This podcast will discuss the combination of azacitidine and pembrolizumab in patients with higher-risk MDS, a personalized prediction model based on clinical and genomic data, the classification of therapy-related MDS as well as the importance of platelet counts as a prognostic factor.
- Azacitidine with Pembrolizumab in Intermediate-1 or Higher-Risk MDS
- Personalized Prediction Model in MDS
- Therapy-Related MDS Deserves Specific Sub-classification
- Influence of Platelet Count on Prognosis in MD